Grifols SA (GRFS)
7.62
+0.15
(+2.01%)
USD |
NASDAQ |
May 15, 14:23
Grifols Enterprise Value: 16.69B for May 14, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 14, 2024 | 16.69B |
| May 13, 2024 | 16.56B |
| May 10, 2024 | 16.37B |
| May 09, 2024 | 16.33B |
| May 08, 2024 | 16.26B |
| May 07, 2024 | 16.23B |
| May 06, 2024 | 16.38B |
| May 03, 2024 | 16.07B |
| May 02, 2024 | 15.95B |
| May 01, 2024 | 16.22B |
| April 30, 2024 | 15.98B |
| April 29, 2024 | 16.01B |
| April 26, 2024 | 15.95B |
| April 25, 2024 | 15.87B |
| April 24, 2024 | 15.95B |
| April 23, 2024 | 16.01B |
| April 22, 2024 | 15.89B |
| April 19, 2024 | 15.88B |
| April 18, 2024 | 16.05B |
| April 17, 2024 | 16.08B |
| April 16, 2024 | 16.22B |
| April 15, 2024 | 16.05B |
| April 12, 2024 | 16.07B |
| April 11, 2024 | 16.13B |
| April 10, 2024 | 16.35B |
| Date | Value |
|---|---|
| April 09, 2024 | 16.49B |
| April 08, 2024 | 16.56B |
| April 05, 2024 | 16.43B |
| April 04, 2024 | 16.27B |
| April 03, 2024 | 16.29B |
| April 02, 2024 | 16.22B |
| April 01, 2024 | 16.15B |
| March 28, 2024 | 16.15B |
| March 27, 2024 | 16.13B |
| March 26, 2024 | 16.01B |
| March 25, 2024 | 15.93B |
| March 22, 2024 | 15.84B |
| March 21, 2024 | 16.22B |
| March 20, 2024 | 15.88B |
| March 19, 2024 | 15.73B |
| March 18, 2024 | 15.72B |
| March 15, 2024 | 15.78B |
| March 14, 2024 | 15.52B |
| March 13, 2024 | 15.92B |
| March 12, 2024 | 15.88B |
| March 11, 2024 | 16.21B |
| March 08, 2024 | 16.37B |
| March 07, 2024 | 15.42B |
| March 06, 2024 | 15.33B |
| March 05, 2024 | 15.80B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
12.09B
Minimum
May 31 2019
24.17B
Maximum
Feb 21 2020
18.87B
Average
19.06B
Median
Aug 27 2020
Enterprise Value Benchmarks
| DBV Technologies SA | 12.08M |
| Adaptimmune Therapeutics PLC | 136.91M |
| Akari Therapeutics PLC | 8.041M |
| Biodexa Pharmaceuticals Plc | -2.783M |
| NuCana PLC | -13.74M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 60.30M |
| Revenue (Quarterly) | 1.906B |
| Total Expenses (Quarterly) | 1.812B |
| EPS Diluted (Quarterly) | 0.0888 |
| Gross Profit Margin (Quarterly) | 38.98% |
| Profit Margin (Quarterly) | 3.16% |
| Earnings Yield | 4.08% |
| Operating Earnings Yield | 15.54% |
| Normalized Earnings Yield | 2.798 |